Pharmacist-Led Medication Therapy Management: A Review of Its Effectiveness in Improving Patient Outcomes

Dr. Ahmmad F. Alkaim[1], and Dr. Maytham Khan[2]

[1] *College of Pharmacy, University of Baghdad, Iraq.*

[2] *College of Pharmacy, University of Baghdad, Iraq.*

Received: 11/September/2024; Revised: 13/October/2024; Accepted: 14/November/2024; Published: 20/December/2024

Abstract

Cardiologists at the HF facility got exhaustive prescription survey notes as a component of the HF drug specialist medicine audit administration. 64 mediation patients who had a drug specialist prescription survey and 64 control patients who didn't got an earlier drug specialist audit had their graphs looked into reflectively. The quantity of DRPs found per patient in the mediation bunch fourteen days following the drug specialist prescription audit was the principal result, and it was contrasted with the number found per patient in the benchmark group. Following the scientific expert mediation, the mean DRPs per patient in the mediation bunch dropped from 2.80 to 1.95. The mean DRPs for every patient in the control and mediation bunches were 2.55 DRPs per patient versus 1.95 DRPs per patient, separately, with a genuinely massive distinction (P = 0.016). Drug adherence (78%), renal meds (67%), hypertension (58%), and cardiovascular breakdown DRPs (55%) had the best endorsement rates. High-influence DRP ideas made up the larger part in both the mediation (87%) and control gatherings (87%) gatherings.

Keywords: Medication, Drug-related Problems, Pharmaceutical.

1 INTRODUCTION

Medication reviews are frequently suggested as a way to raise the safety and effectiveness of pharmacological therapy. For sure, different randomized controlled examinations (RCTs), all led in everyday consideration or during hospitalization, have shown that prescription audits as the single mediation can lessen the quantity of DRPs somewhat (Zhao et al., 2021). DRPs found during drug surveys, nonetheless, have not been shown to be associated with lower mortality or re-hospitalization rates. Huiskes et al., (2020) Furthermore, the majority of reported RCTs that solely included medication reviews as an intervention had negligible to no impact on clinical outcomes including death and (re)hospitalization (Dürr et al., 2021). Reducing drug-related problems (DRPs) can optimise patients' medications, according to recent medication review intervention trials conducted in outpatient clinics with patient engagement and follow-up (Houlind et al., 2020). A comprehensive clinical assessment of patients is provided by these outpatient clinics, which have been established in most regions of Denmark in recent years. This has improved care and contributed to a decrease in the number of acute hospital admissions for patients with multiple medical conditions. Also, research has shown the way that joint effort between clinical scientific experts and doctors can fundamentally work on the propriety of medicines across clinical disciplines in figure 1.



Figure 1: Pharmacist Role

Certain clinical short-term centers comprise of multidisciplinary groups of specialists, medical caretakers, physicists and physiotherapists, while others are restricted to simply specialists and attendants. Especially for patients with a few ailments, these short-term centers go about as an indispensable course among essential and optional consideration offices and are intended to make patient follow-up more straightforward (Dharmarajan et al.,2020). Finding out whether clinical chemists and doctors who follow up in subacute outpatient clinics (SMOCs) could jointly deprescribe medication for multimorbid patients was the goal of this pilot randomised controlled experiment. Deng et al., (2022) It is stated that "events or circumstances related to medication therapy that actually or potentially interfere with a desired health outcome" are known as drug-related difficulties (DRPs). Strong evidence has indicated that DRP-related poor effects constitute a serious health issue. The majority of drug-related problems (DRPs) that result from hospital stays and ER visits can be avoided. Nevertheless, there is still a need for an efficient drug review process to identify DRPs. Global population ageing is a problem that cannot be solved. As people age, their functional reserves and adaptability decline. Older patients frequently have multiple medical conditions that need to be treated concurrently. Polypharmacy, which is profoundly common in more established patients, raises the gamble of unfavorable medication occasions, conceivable medication collaborations, and medication blunders, as well as dreariness and mortality. Pharmacists' contribution in understanding consideration fundamentally further develops prescription adherence rates, diminishes medication related issues, and improves generally speaking wellbeing results. These mediations frequently include customized drug audits, patient schooling, and progressing observing of prescription use. Drug specialist drove MTM mediations likewise lead to a decrease in medical care costs, as further developed adherence diminishes hospitalizations and crisis division visits

2 RELATED WORK

In 80.6% of patients, there was at least one medication change between CMP and physician-documented MP. It is difficult to compare these results with earlier studies since most investigations investigated inconsistencies between MP and patient-reported medication data or electronic pharmacy records. In 76%–96% of patients, there are differences between the medicine that the patient reports taking and the MP that the doctor documents (Lea et al., 2020). The shifts between MP/patient-specified medication and CMP in our study are the consequence of a multidisciplinary integration agreement, in contrast to documented inconsistencies that might be inadvertent due to a lack of communication or awareness amongst clinicians. Page et al., (2021) Patients with MMD frequently need polypharmacy. The term "polypharmacy" typically describes the concurrent use of five or more prescription and over-the-counter pharmaceuticals, herbal remedies, and other health items (Shrestha et al., 2022). Every year, the number of elderly individuals and the prevalence of MMD rise, and with them, so does the need for several medications (Hoel et al., 2021).

Polypharmacy rates in senior MMD patients in the Chinese community vary from 33.1 to 75.3% (Li et al., 2021), but polypharmacy rates in hospitalized patients range from 48.0 to 95.7%. Furthermore, polypharmacy is a significant method in the treatment and management of MMD. However, it may also have negative consequences, such as increased medication-related difficulties (DRPs), poor patient compliance, higher rehospitalization rates, and longer hospital stays. Medication therapy management (MTM) is the process by which chemists and other pharmacists with specific knowledge provide a variety of specialized services, including medication education, treatment consulting, and medication counseling. To improve treatment outcomes, pharmaceutical errors are avoided, and patients are taught how to control their own medications. TMTM comprises of five essential parts: drug treatment audit (MTR), individual medicine record, prescription activity plan, mediation and reference, documentation and follow-up, and tending to patients' DRPs. The troubles of MMD and polypharmacy have started worldwide interest. In any case, patients who are going through various treatment are bound to profit from MTM administrations. Albeit clinical proof and treatment rules obviously require the utilization of proof-based drugs for patients with HF, for example, angiotensin-changing over catalyst inhibitors (ACEIs) and beta-blockers, these therapies are known to be suboptimal when dispensed in real-world clinical practice (Gunter, 1999).8 The Heart Failure National Registry (ADHERE) collects HF case data from over 275 institutions in the United States, totaling over 40,000 patients hospitalized with HF.

According to data from the third quarter of 2004, physicians prescribed ACEIs to 54% of patients upon discharge, with approximately 68% using ACEIs or angiotensin receptor blockers (ARBs).9 In addition, beta-blockers were prescribed by physicians to 72% of released patients.9 These findings are positive when compared to previously published data, indicating a more appropriate utilization of evidence-based therapy. Although prescribing habits appear to be improving over time, the usage of ACE inhibitors and beta-blockers is still inadequate for the most vulnerable individuals.The Enhanced

Feedback for Effective Cardiac Therapy research looked at a population-based cohort of heart failure patients (9,942 patients) who were hospitalized in Ontario, Canada, from 1999 to 2001. Patients having a left ventricular ejection fraction less than 40% and those under the age of 79 (1,418 patients) were assessed.

3 METHODS AND MATERIALS

The study was carried out with an emphasis on community chemists' MTM delivery. It makes use of a narrative review process. In order to find gaps or contradictions in a body of information, narrative reviews offer a critical and impartial appraisal of the state of knowledge on a subject and summarize patterns and trends in the literature. The salient features of the present MTM implementation and delivery issues faced by community chemists are presented.

A solitary community, forthcoming randomized controlled study was led to evaluate the viability of drug specialist drove MTM on further developing medicine adherence and medical clinic confirmation in patients with type 2 diabetes mellitus who visited the diabetes sickness follow-up care center of UoGRTH from February 1 to July 30, 2016. UoGRTH is situated in Gondar town, northwest Ethiopia. It is the locale's just reference community with various expert facilities, including pediatrics, medical procedure, gynecology, psychiatry, HIV therapy, disease, short term facilities, and diabetic subsequent centers; it as of now gives short term care to north of 10,000 diabetic patients each year.In expansion, the emergency clinic offers clinical drug store administrations in a few facilities, including short term care, psychiatry, inward medication, and a medication data focus.

Statistical Methods

The characteristics of each patient are shown as means plus standard deviations (SD). Chi-squared tests were used to compare proportions between patient groups. When the expected cell frequencies were fewer than five, the Fisher exact test was applied. Paired t tests were performed to investigate differences in the total number of drugs used by patients over various time periods. All statistical tests had a significance level of $p < 0.05$.

Appraisal of Result Measures

In the mediation bunch, the quantity of real DRPs at T0 was resolved through a telephone conversation with the patient multi week before the cardiologist visit, as well as a contact structure shared by the drug specialist and the cardiologist. One month after the patient's cardiologist visit (T1), the not entirely set in stone in the event that the genuine DRPs at T0 had been settled. The underlying step was to scan the clinical record for data about DRPs, trailed by a phone evaluation with the patient. In the event that it was muddled on the off chance that a particular DRP had been settled, the drug specialist reached the cardiologist or another prescriber through telephone. Patients in the benchmark group went to the short term drug store after their cardiology arrangement and were approached to finish up a similar poll viewing their medication use as the mediation patients. The drug store staff

encouraged them to survey the issue prior to seeing a cardiologist. The short-term drug specialist then played out an electronic organized prescription survey of the patient's complete meds, using the patient's clinical record and poll data to distinguish plausible DRPs. The drug specialist did this medicine appraisal soon after talking with the cardiologist, however no suggestions were made to address any potential DRPs that were found. One month following the cardiology discussion, the drug specialist talked with the patient via telephone.

Following her interview with her cardiologist, the control patient went to the outpatient pharmacy and was asked to fill out the same questionnaire as the intervention patients regarding her experience using medications. The pharmacy staff instructed her to recall the situation before her cardiologist visit. To identify possible DRPs, the short-term drug specialist then directed a modernized organized medicine survey of the patient's complete prescription use utilizing information from the poll and the patient's clinical record. The pharmacist reviewed the medications right after the cardiologist's visit, but no suggestions for resolving the potential DRPs were given. The patient and the pharmacist spoke over the phone one month following the cardiologist's consultation.

DE Prescribed Medications

The control group received prescriptions for five different DE drugs in total. Out of these, four (80%) were conventional drugs, and one (20%) was Prorenata (P.R.N.). 100% of the five prescriptions were stopped. Colchicine, folic acid, insulin, venlafaxine, and alogliptin were the drugs in question. Thirty-seven DE medicines were prescribed to the intervention group. Of these, seven (19%) were P.R.N. drugs and thirty (81%) were normal prescriptions. All told, the doses of eight (22%) and 29 of the 37 (78%) medications were lowered. The most often given DE drug kinds in the intervention group are displayed in Table 1.

Table 1. Most Frequently DE Prescribed Medications in the Intervention Group

Class and Medication	Frequency n (%)
Analgesics	14 (37.8)
Paracetamol	5 (13.5)
NSAID	4 (10.8)
Gabapentin	2 (5.4)
Cardiovascular	9 (24.3)
Beta blockers	4 (10.8)
Antihypertensives	2 (5.4)

Detection of DRPs

Pharmacists assessed medication using their knowledge and experience. Two pharmacists carried out the classification process separately, and a senior pharmacist verified the validity and reliability of their assessments. Following an evaluation of each medication's indications, dosage, adherence,

adverse effects, and therapeutic impact, DRPs were documented. Patients received additional advice from pharmacists to maximize their pharmacotherapy. The Pharmaceutical Care Network Europe (PCNE) classification of DRPs V8.03 was used to assess DRPs and recommendations with regard to problem, causes, intended interventions, and acceptability of the interventions.

Outpatient HF Infusion Clinic

For third-party payers like Medicare and private insurers, readmission rates for ADHF are a crucial benchmark figure. Planned intravenous diuretic delivery in an outpatient setting can lower heart failure hospitalizations and readmissions within 30 days, according to a small pilot research. 27 Establishing such clinics is something that several hospitals in the US are interested in doing. These kinds of facilities give pharmacists the chance to work together with other medical specialists to create infusion protocols and enhance other forms of medication. Furthermore, by conducting medication reconciliations, educating patients, and enhancing medication adherence, these clinics give pharmacists the opportunity to interact directly with patients.

Development of Disease Management Pathway

It has been shown that disease management pathways effectively enhance care, particularly for high-risk, high-cost, and high-volume conditions.12 HF is seen as a high-risk, high-cost, high-volume diagnosis. Thus, we expect that these pathways will increase the effectiveness of care for patients with heart failure (HF), even if there aren't any particular clinical trials on pharmacists creating and utilizing disease management pathways to enhance HF patient care. As part of a team that assesses the pathway that necessitates appropriate drug usage, pharmacists are crucial. The health system's formulary should serve as the basis for choosing a standard set of medications for the pathway, and this should be done through a process that allows for the incorporation of new knowledge on disease treatment, including medication therapy. Pharmacists can make sure that interventions are in line with hospital board standards, local pharmacy regulations, and other policies by integrating evidence-based, logical, and economical treatments into critical care pathways. Additionally, pharmacists are able to create medication usage assessments prospectively, which enables them to evaluate important care pathway components that affect safety, adherence, variation, and effectiveness (with predetermined outcomes).follow-up treatment after release, clinics, and home visits.

Ethical Considerations

This study has ethical approval from the Ethics Research Committee (ERC) of the study setting (IRB/IEC/0004553, dated 24 February 2022). The research protocol was entered into the ClinicalTrials.gov database under the NCT05291026 clinical trial registration number. Donald Morisky granted permission to utilize the MMAS-8 scale as a standard instrument for this research.



Figure 2: Conceptual Framework

The reduction of glycated hemoglobin (HbA1C) was the main outcome, as indicated by Figure 2 (conceptual framework). The participants' knowledge, self-reported medication adherence, and pharmacy refill adherence were the secondary outcomes. HbA1C values were taken from patient records at the baseline and endpoint. Information about medicine tops off was removed from patient records toward the finish of every month. Because of its demonstrated unwavering quality in similar exploration, drug store top off adherence was used as a roundabout mark of prescription adherence. The name, measurements, and date of the patient's organization of the professionally prescribed prescription, as well as its solidarity, were undeniably noted by the analysts. Adherence to medicine reorder arrangements was determined utilizing the Level of Days Covered approach. A day is "covered" when every one of the recommended prescriptions are accessible to the patient. Thus, for each top off cycle (being month to month in the Diabetes Facility), the PDC is determined.

4 DISCUSSION

Information was obtained for 150 patients. 74.0% of the population was female, and the mean (SD) age was 54.4 (19.4) years. At enrollment, they had a mean (SD) of 6.1 (3.1) medical problems and were using a mean of 9.3 (4.6) drugs. Eighty-six drug-related problems were categorized into seven categories: dose too high (5.3%), wrong medicine (13.2%), inappropriate adherence (25.9%), needs further therapy (22.0%), adverse drug reaction (11.1%), and unneeded drug therapy (12.9%). Of the 659 recommendations made by pharmacists to modify drug therapy, 313 (47.4%) were approved by doctors overall. The highest percentages of agreement were for stopping or switching medications (50.3% and 50.0%, respectively), while the lowest percentage was for starting a new medicine (41.7%).

Table 2: Classification of DRPs Identified According to PCNE V8.03 (n = 525)

Characteristics	Total (*n* = 244)
Demographics	
Age (y), mean ± SD	72.54 ± 9.96
65–79 y, *n* (%)	204 (83.61%)
≥80 y, *n* (%)	40 (16.39%)
Female, *n* (%)	143 (58.61%)
Number of medications taken, mean ± SD	8.76 ± 4.35
Active chronic conditions, *n* (%)	
Hypertension	171 (70.08%)
Heart disease	138 (56.56%)
Hyperlipidaemia	73 (29.92%)
Diabetes mellitus	70 (28.69%)

A total of 525 DRPs were found during the study period, as indicated in Table 2. There were 2.15 DRPs found on average for each subject. The majority of DRPs were related to treatment effectiveness (53.71%) and treatment safety (33.90%). The selection of drugs (71.43%) and doses (20.57%) was the primary cause of DRPs. Drug substitution (48.76%) was the most often advised strategy, followed by dosage modification (24.76%) and initiation of medication (11.62%). 90.48% of the patients had their interventions fully executed, and 92.38% of the patients accepted the therapies.

5 CONCLUSION

Pharmacist assessments of an MTM program's effects inside a sizable integrated health care system indicate that the initiative was linked to both cost savings and better clinical results. There was excellent patient satisfaction with the program. To sum up, MTM interventions conducted by pharmacists are essential for raising patient adherence and boosting health results. The advantages of drug specialist cooperation in quiet consideration are accentuated in this precise review, which additionally underscores that it is so critical to integrate MTM administrations into standard clinical practice. By enhancing solution regimens, giving patient instruction, and conveying proceeding with help, drug specialists can contribute extensively to expanding prescription adherence rates and in general persistent wellbeing. To guarantee the broad adoption of pharmacist-led MTM interventions in healthcare systems, more investigation is required into the scalability and sustainability of these approaches.

REFERNCES

[1] Zhao, X., Xu, R., Wang, Y., Zhu, W., Hu, H., Shen, Z., ... & Zhang, J. (2021). Impacts of pharmacists-managed oncology outpatient clinic on resolving drug-related problems in ambulatory neoplasm patients: a prospective study in China. *INQUIRY: The Journal of Health Care Organization, Provision, and Financing*, *58*, 00469580211009662. https://doi.org/10.1177/00469580211009662

[2] Huiskes, V. J. B., van den Ende, C. H. M., Kruijtbosch, M., Ensing, H. T., Meijs, M., Meijs, V. M. M., ... & van den Bemt, B. J. F. (2020). Effectiveness of medication review on the number of drug-related problems in patients visiting the outpatient cardiology clinic: A randomized controlled trial. *British journal of clinical pharmacology*, *86*(1), 50-61. https://doi.org/10.1111/bcp.14125

[3] Houlind, M. B., Andersen, A. L., Treldal, C., Jørgensen, L. M., Kannegaard, P. N., Castillo, L. S., ... & Petersen, J. (2020). A collaborative medication review including deprescribing for older patients in an emergency department: a longitudinal feasibility study. *Journal of Clinical Medicine*, *9*(2), 348. https://doi.org/10.3390/jcm9020348

[4] Dharmarajan, T. S., Choi, H., Hossain, N., Munasinghe, U., Lakhi, F., Lourdusamy, D., ... & Russell, R. O. (2020). Deprescribing as a clinical improvement focus. *Journal of the* American *Medical Directors Association*, *21*(3), 355-360. https://doi.org/10.1016/j.jamda.2019.08.031

[5] Deng, Z. J., Ding, Y. F., Peng, S. S., Wang, L., & Wei, A. H. (2022). Multiple beneficial outcomes of medication therapy management interventions in randomized control trials and non-randomized control trials: A protocol for systematic review and meta-analysis. *Medicine*, *101*(43), e31491.

[6] Dürr, P., Schlichtig, K., Kelz, C., Deutsch, B., Maas, R., Eckart, M. J., ... & Fromm, M. F. (2021). The randomized AMBORA trial: Impact of pharmacological/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents. *Journal of Clinical Oncology*, *39*(18), 1983-1994. https://doi.org/10.1200/JCO.20.03088

[7] Gunter, M. J. (1999). Clinical Practice Improvement. *The American journal of managed care*.

[8] Lea, M., Mowé, M., Molden, E., Kvernrød, K., Skovlund, E., & Mathiesen, L. (2020). Effect of medicines management versus standard care on readmissions in multimorbid patients: a randomised controlled trial. *BMJ open*, *10*(12), e041558. https://doi.org/10.1136/bmjopen-2020-041558

[9] Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., ... & Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *bmj*, *372*. https://doi.org/10.1136/bmj.n71

[10] Shrestha, S., Shrestha, R., Ahmed, A., Sapkota, B., Khatiwada, A. P., Christopher, C. M., ... & Paudyal, V. (2022). Impact of pharmacist services on economic, clinical, and humanistic outcome (ECHO) of South Asian patients: a systematic review. *Journal of Pharmaceutical Policy and Practice*, *15*(1), 37.

[11] Hoel, R. W., Connolly, R. M. G., & Takahashi, P. Y. (2021, January). Polypharmacy management in older patients. In *Mayo Clinic Proceedings* (Vol. 96, No. 1, pp. 242-256). Elsevier. https://doi.org/10.1016/j.mayocp.2020.06.012

[12] Li, L. I., LI, S., WEI, Y., ZHANG, Y., & YAN, L. E. (2021). Prevalence and factors associated with polypharmacy in community-dwelling older people: a systematic review. *Chinese General Practice*, *24*(25), 3161. https://doi.org/10.12114/j.issn.1007-9572.2021.00.204